You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

  • Technology appraisal guidance
  • Reference number: TA243
  • Published:  25 January 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive Appendix B: proposal paper presented to the Institute's Guidance Executive
16 June 2014
(444.3 Kb 9 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 13 June 2014

Back to top